• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now

    9/24/24 7:00:00 AM ET
    $AEMD
    $ASPI
    $BNRG
    $CIA
    Medical/Dental Instruments
    Health Care
    Major Chemicals
    Industrials
    Get the next $AEMD alert in real time by email

    MIAMI, Sept. 24, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 75th Emerging Growth Conference on September 25 & 26, 2024.

    The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.

    Register for the Conference here.

    Submit Questions for any of the presenting companies to:

    [email protected]

    For updates, follow us on Twitter

    Sponsors:

    QuoteMedia - Keep Investors Informed with Dynamic Plug and Play IR Solutions

    (844) 485-8200

    [email protected]

    QuoteMedia.com

    Day 1

    September 25, 2024

    8:45

    Virtual Lobby opens.

    Register for the Conference. If you already registered, go back to the registration link and click "Already registered" and enter your email.

    9:00

    Introduction

    9:05 – 9:35

    U.S. Energy Corporation (NASDAQ:USEG)

    Keynote speaker: Ryan Smith, President, CEO & Director

    9:40 – 10:10

    Brenmiller Energy, Ltd. (NASDAQ:BNRG)

    Keynote speaker: Nir Brenmiller, COO

    10:15 – 10:45

    Sky Harbour Group Corporation (NYSE:SKYH)

    Keynote speakers: Tal Keinan, Founder and CEO & Francisco X. Gonzalez, CFO

    10:50 - 11:20

    Star Jets International, Inc. (OTC:JETR)

    Keynote speaker: Richard Sitomer, CEO

    11:25 - 11:55

    Caledonia Mining Corporation Plc. (NYSE:CMCL)

    Keynote speaker: John Mark Learmonth – CEO

    12:00 – 12:30

    Zenith Epigenetics Ltd.

    Keynote speaker: Donald J. McCaffrey – President & CEO

    12:35 - 1:05

    Aethlon Medical, Inc. (NASDAQ:AEMD)

    Keynote speakers: Jim Frakes – Acting CEO and CFO & Steven LaRosa – Chief Medical Officer

    1:10 - 1:40

    Vivani Medical, Inc. (NASDAQ:VANI)

    Keynote speaker: Adam Mendelsohn PHD, CEO

    1:45 - 2:15

    Vista Gold Corp. (NYSE:VGZ) (TSX:VGZ)

    Keynote speaker: Frederick Earnest – CEO

    2:20 – 2:50

    Evanesce

    Keynote speaker: Douglas Horne, Founder & CEO

    2:55 – 3:05

    GeoVax Labs, Inc. (NASDAQ:GOVX)

    Keynote speaker: David Dodd, Chairman, President / CEO

    3:10 - 3:20

    BlueRush, Inc. (OTCQB:BTVRF) (TSXV:BTV)

    Keynote speaker: Steve Taylor, CEO

    3:25 - 3:35

    Pure Cycle Corporation (NASDAQ:PCYO)

    Keynote speaker: Mark Harding, President

    3:40 – 3:50

    Peninsula Energy Limited (OTCQB:PENMF) (ASX: PEN)

    Keynote speaker: Wayne W. Heili, MD, CEO & Director

    3:55 – 4:05

    Sucro Limited (OTCQB:SUGRF) (TSXV:SUG)

    Keynote speaker: Don Hill, Chairman

    4:10 – 4:20

    Regen BioPharma Inc. (OTC:RGBP)

    Keynote speakers: David Koos, President / CEO, and Harry M. Lander, Ph.D. Senior Scientific Consultant

    4:25 – 4:35

    Immuron Limited (NASDAQ:IMRN)

    Keynote speaker: Steve Lydeamore, CEO

    4:40 – 4:50

    Peloton Minerals Corp. (OTCQB:PMCCF) (CSE:PMC)

    Keynote speaker: Edward L. Ellwood, President, CEO & Director

    Day 2

    September 26, 2024

    8:45

    Virtual Lobby opens.

    Register for the Conference. If you already registered, go back to the registration link and click "Already registered" and enter your email.

    9:00

    Introduction

    9:05 – 9:35

    uCloudlink Group, Inc. (NASDAQ:UCL)

    Keynote speakers: Ivan Shi, CFO, & Daniel Gao, IRD

    9:40 – 10:10

    Alta Global Group Limited (NYSE:MMA)

    Keynote speaker: Nick Langton, CEO

    10:15 – 10:45

    ASP Isotopes Inc. (NASDAQ:ASPI)

    Keynote speaker: Paul Elliot Mann, CEO

    10:50 - 11:20

    Reconnaissance Energy Africa, Ltd. (OTCQX:RECAF) (TSXV:RECO)

    Keynote speaker: Brian Reinsborough, President and CEO

    11:25 - 11:55

    Bioxytran, Inc. (OTCQB:BIXT)

    Keynote speakers: Mike Sheikh, Executive Vice President Business Development

    12:00 - 12:30

    M2i Global, Inc., (OTCQB:MTWO)

    Keynote speakers: Major General (Ret) Alberto Rosende, CEO & Doug Cole, Executive Chairman

    1:10 - 1:40

    Nova Minerals Limited (NASDAQ:NVA) (OTC:NVAAF) (ASX: NVA)

    Keynote speaker: Christopher Gerteisen – CEO & Executive Director

    1:45 - 2:15

    Sono Group N.V. (OTCQB:SEVCF)

    Keynote speaker: George O'Leary, Managing Director, CEO and CFO

    2:20 – 2:50

    Birch Co. (OTC:ATWT)

    Keynote speaker: Josh Ploch, CEO

    2:55 – 3:05

    Citizens, Inc. (NYSE:CIA)

    Keynote speakers: Jon Stenberg, President / CEO, and Jeff Conklin, CFO

    3:10 - 3:20

    Interstellar Communication Holdings 

    Keynote speakers: Seda Hewitt, Space Ambassador, Harri Laitinen, CEO of Planix Oy., and Lijie Zhu, Founder and managing director of Dragon Gate Investment Partners

    3:25 - 3:35

    CytoMed Therapeutics, Ltd. (NASDAQ:GDTC)

    Keynote speaker: Peter Choo, Chairman

    3:40 – 3:50

    Canoo Inc.'s (NASDAQ:GOEV) 

    Keynote speaker: Greg Ethridge, CFO

    3:55 – 4:05

    Unusual Machines, Inc. (NYSE:UMAC)

    Keynote speaker: Allan Evans, CEO

    4:10 – 4:20

    Gossamer Bio, Inc. (NASDAQ:GOSS)

    Keynote speaker: Bryan Giraudo, CFO & COO

    4:25 – 4:35

    Cyios Corp. (OTC:CYIO)

    Keynote speaker: John O'Shea, Chairman

    Visit the following link to register. You will then receive an email containing the link and time to sign into the conference.

    Register for the Conference here.

    Submit Questions for any of the presenting companies to:

    [email protected]

    Replays: Subscribe to our YouTube Channel

    About EmergingGrowth.com

    Founded in 2009, Emerging Growth.com quickly became a leader in its space and has developed an extensive history of identifying emerging growth companies that can be overlooked by the investment community.

    About the Emerging Growth Conference

    The Emerging Growth Conference is an effective way for public companies to engage with the investment community regarding their Company, new products, services and other major announcements from anywhere, in an effective and time efficient manner.

    All sessions are conducted through video webcasts. Our conference serves as a vehicle for Emerging Growth to build relationships with our existing and potential clients. Accordingly, a certain number of the presenting companies are our current clients, and some may become our clients in the future. In exchange for services we provide, our clients pay us fees in the form of cash and securities, and we may currently have, or in the future may have investments in the securities of certain of the presenting companies. Finally, certain of the presenting companies have paid us a fee to secure a presentation time slot or to present generally. The presentations to be delivered by the presenting companies (including any virtual handouts of written materials) have not been approved, endorsed by or otherwise reviewed by EmergingGrowth.com nor should they in any way be construed to have been made in connection with an offer to sell or a solicitation of an offer to buy securities. Please consult an investment professional before investing in anything viewed on the Emerging Growth Conference or on EmergingGrowth.com.

    If you believe or know of a company that might fit our audience, contact us here.

    Thank you for your interest in our conference, and we look forward to your participation in future conferences.

    Contact:

    Emerging Growth

    Phone: 1-305-330-1985

    Email: [email protected]



    Primary Logo

    Get the next $AEMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEMD
    $ASPI
    $BNRG
    $CIA

    CompanyDatePrice TargetRatingAnalyst
    GeoVax Labs Inc.
    $GOVX
    2/19/2026Buy → Hold
    D. Boral Capital
    Gossamer Bio Inc.
    $GOSS
    1/28/2026$9.00Overweight
    Barclays
    ASP Isotopes Inc.
    $ASPI
    12/4/2025$13.00Overweight
    Cantor Fitzgerald
    Sky Harbour Group Corporation
    $SKYH
    10/27/2025$13.00Buy
    BTIG Research
    Gossamer Bio Inc.
    $GOSS
    9/10/2025$9.00Neutral → Buy
    UBS
    Unusual Machines Inc.
    $UMAC
    8/19/2025$15.00Buy
    Needham
    Gossamer Bio Inc.
    $GOSS
    7/14/2025$11.00Sector Outperform
    Scotiabank
    Aethlon Medical Inc.
    $AEMD
    7/7/2025$1.50Neutral
    H.C. Wainwright
    More analyst ratings

    $AEMD
    $ASPI
    $BNRG
    $CIA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GeoVax Labs downgraded by D. Boral Capital

    D. Boral Capital downgraded GeoVax Labs from Buy to Hold

    2/19/26 8:44:06 AM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Gossamer Bio with a new price target

    Barclays initiated coverage of Gossamer Bio with a rating of Overweight and set a new price target of $9.00

    1/28/26 7:16:48 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on ASP Isotopes with a new price target

    Cantor Fitzgerald initiated coverage of ASP Isotopes with a rating of Overweight and set a new price target of $13.00

    12/4/25 8:40:44 AM ET
    $ASPI
    Major Chemicals
    Industrials

    $AEMD
    $ASPI
    $BNRG
    $CIA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Gregg bought $1,983,333 worth of shares (1,866,492 units at $1.06) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    2/17/26 6:01:47 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Williams Gregg bought $1,999,999 worth of shares (1,351,351 units at $1.48) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    1/28/26 10:01:22 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Williams Gregg bought $1,983,334 worth of shares (1,737,765 units at $1.14) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    1/20/26 9:00:37 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AEMD
    $ASPI
    $BNRG
    $CIA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Safe Pro Group Projects Over 500% Year-Over-Year Q1 2026 Revenue Growth Following U.S. Government Award for AI Edge Processing Systems

    AVENTURA, Fla., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Safe Pro Group Inc. (NASDAQ:SPAI) ("Safe Pro" or the "Company"), an artificial intelligence ("AI") defense technology company delivering drone-powered situational awareness and threat detection solutions, today announced that it expects revenue in the first quarter of 2026 to increase over 500% year-over-year, driven by initial deliveries under a recently awarded U.S. Government subcontract supporting deployment of the Company's AI-Powered Edge Processing platform. The Company believes it is entering a commercial and government adoption inflection point, transitioning from development-stage operations into scaling revenue generation and op

    2/23/26 8:05:00 AM ET
    $ONDS
    $SPAI
    $UMAC
    Radio And Television Broadcasting And Communications Equipment
    Technology
    Industrial Specialties
    Health Care

    Aethlon Medical to Present on the Emerging Growth Conference on February 25th 2026

    Aethlon invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation on the Emerging Growth Conference.SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, is pleased to announce that it has been invited to present on the Emerging Growth Conference on February 25, 2026 at 12:30-1:00 PM ET. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO and CFO, Jim Frakes in

    2/23/26 8:01:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension

    - Seralutinib demonstrated a placebo-adjusted improvement in Six-Minute Walk Distance (6MWD) of +13.3 meters at Week 24 (p = 0.0320), missing the prespecified alpha threshold of 0.025 - - At week 24, patients receiving seralutinib had a median change of +28.2 meters from baseline, while patients receiving placebo had a median change from baseline of +13.5 meters - - Consistent with the TORREY Study, prespecified intermediate and high-risk subgroup (n = 234) showed a +20.0 meter placebo-adjusted 6MWD improvement (p = 0.0207), with 3 of 4 key secondary endpoints achieving p < 0.0125 - - Overall treatment effect was most pronounced in North America (n = 75), with a +25.9m placebo-adjuste

    2/23/26 8:00:00 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $ASPI
    $BNRG
    $CIA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Gonzalez Francisco was granted 203,390 shares and covered exercise/tax liability with 15,320 shares, increasing direct ownership by 36% to 709,588 units (SEC Form 4)

    4 - Sky Harbour Group Corp (0001823587) (Issuer)

    2/20/26 8:14:41 PM ET
    $SKYH
    Real Estate
    Finance

    Chief Executive Officer Keinan Tal was granted 225,989 shares and covered exercise/tax liability with 6,445 shares, increasing direct ownership by 436% to 269,846 units (SEC Form 4)

    4 - Sky Harbour Group Corp (0001823587) (Issuer)

    2/20/26 8:14:03 PM ET
    $SKYH
    Real Estate
    Finance

    Chief Accounting Officer Schmitt Michael Weber was granted 33,898 shares and covered exercise/tax liability with 3,011 shares, increasing direct ownership by 59% to 83,441 units (SEC Form 4)

    4 - Sky Harbour Group Corp (0001823587) (Issuer)

    2/20/26 8:13:06 PM ET
    $SKYH
    Real Estate
    Finance

    $AEMD
    $ASPI
    $BNRG
    $CIA
    SEC Filings

    View All

    SEC Form F-3 filed by Brenmiller Energy Ltd

    F-3 - Brenmiller Energy Ltd. (0001901215) (Filer)

    2/23/26 4:46:47 PM ET
    $BNRG
    Building Products
    Industrials

    Aethlon Medical Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - AETHLON MEDICAL INC (0000882291) (Filer)

    2/23/26 4:15:32 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Gossamer Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Gossamer Bio, Inc. (0001728117) (Filer)

    2/23/26 8:30:24 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $ASPI
    $BNRG
    $CIA
    Financials

    Live finance-specific insights

    View All

    Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension

    - Seralutinib demonstrated a placebo-adjusted improvement in Six-Minute Walk Distance (6MWD) of +13.3 meters at Week 24 (p = 0.0320), missing the prespecified alpha threshold of 0.025 - - At week 24, patients receiving seralutinib had a median change of +28.2 meters from baseline, while patients receiving placebo had a median change from baseline of +13.5 meters - - Consistent with the TORREY Study, prespecified intermediate and high-risk subgroup (n = 234) showed a +20.0 meter placebo-adjusted 6MWD improvement (p = 0.0207), with 3 of 4 key secondary endpoints achieving p < 0.0125 - - Overall treatment effect was most pronounced in North America (n = 75), with a +25.9m placebo-adjuste

    2/23/26 8:00:00 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update

    Clinical and research programs continue to advance, supported by year-to-date cost efficiencies Conference Call Today at 4:30 p.m. ET SAN DIEGO, Feb. 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2025, and provided an update on recent developments.  Key Highlights Maintained Nasdaq Listing: Continued compliance with Nasdaq listing requirements, with all prior compliance matters remaining resolved. Clinical Progress: Cohort 2 of the Australian oncology tr

    2/12/26 4:15:00 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Institutional-Grade Token Architecture Positions Companies at the Center of Digital Finance

    Scalable, compliant infrastructure supports demand for regulated digital assets for growing number of industries  Market News Updates News Commentary NEW YORK, Feb. 4, 2026 /PRNewswire/ -- Digital finance is moving fast, and institutional-grade token architecture is becoming a core piece of the financial system. Large investors and institutions want digital assets that are secure, compliant, and easy to integrate with traditional finance. Tokenized infrastructure built for institutions helps make that possible by supporting regulated transactions, asset-backed tokens, and scalable platforms designed for real-world use, not just experimentation as Active Companies take notice that may include

    2/4/26 8:45:00 AM ET
    $COIN
    $DJT
    $GNLN
    Finance: Consumer Services
    Finance
    Computer Software: Programming Data Processing
    Technology

    $AEMD
    $ASPI
    $BNRG
    $CIA
    Leadership Updates

    Live Leadership Updates

    View All

    Aethlon Medical to Present on the Emerging Growth Conference on February 25th 2026

    Aethlon invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation on the Emerging Growth Conference.SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, is pleased to announce that it has been invited to present on the Emerging Growth Conference on February 25, 2026 at 12:30-1:00 PM ET. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO and CFO, Jim Frakes in

    2/23/26 8:01:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Military UAV Sector Forecast to Surpass $40+ Billion as Modern Warfare Evolves

    NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - Unmanned aerial vehicles (UAVs), commonly known as drones, have become a transformative technology in modern defense and military operations, reshaping strategies from reconnaissance to precision strike capabilities. Military drones offer armed forces enhanced situational awareness, reduced risk to personnel, and cost-efficient mission profiles across surveillance, target acquisition, logistics, and electronic warfare. As autonomous systems incorporating artificial intelligence and advanced sensor suites continue to mature, they are increasingly integral to networked battlefield operations and force multiplie

    2/19/26 8:30:00 AM ET
    $NOC
    $PRZO
    $UAVS
    Industrial Machinery/Components
    Industrials
    Military/Government/Technical
    Aerospace

    Pure Cycle Corporation Appoints Daniel J. Roller to its Board of Directors

    DENVER, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Pure Cycle Corporation (NASDAQ Capital Market: PCYO) ("Pure Cycle", "we", "us" or "our") announced that a new independent director, Daniel J. Roller, was appointed to its Board of Directors (the "Board"), effective January 14, 2026, expanding the Board from 7 to 8 directors. This appointment, made in cooperation with Maran Capital Management, LLC ("Maran"), which beneficially owns approximately 14.7% of Pure Cycle's common shares, further strengthens the Board and adds new skillsets and capabilities. In connection with this appointment, the Board will form a Strategy and Capital Allocation Committee, to be chaired by Mr. Roller. Mr. Roller, Presid

    1/15/26 8:30:00 AM ET
    $PCYO
    Water Supply
    Utilities

    $AEMD
    $ASPI
    $BNRG
    $CIA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Pure Cycle Corporation

    SC 13D/A - PURE CYCLE CORP (0000276720) (Subject)

    12/5/24 6:15:44 PM ET
    $PCYO
    Water Supply
    Utilities

    Amendment: SEC Form SC 13D/A filed by Brenmiller Energy Ltd

    SC 13D/A - Brenmiller Energy Ltd. (0001901215) (Subject)

    12/5/24 11:18:20 AM ET
    $BNRG
    Building Products
    Industrials

    Amendment: SEC Form SC 13G/A filed by GeoVax Labs Inc.

    SC 13G/A - GeoVax Labs, Inc. (0000832489) (Subject)

    11/14/24 5:10:48 PM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $ASPI
    $BNRG
    $CIA
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Gossamer Bio Inc. on Jun 21

    Gossamer Bio Inc. recently witnessed an insider purchase by COO/CFO Bryan Giraudo, who acquired $59,110 worth of shares consisting of 100,000 units at $0.59 per share. Insider purchases like this can provide valuable insights for investors, indicating confidence from individuals within the company about its future prospects. Examining previous insider transactions, on 2024-03-19, insiders Peterson Caryn and Aranda Richard each sold $5,343 worth of shares at $1.33, leading to a decrease in their direct ownership percentages. Similarly, on 2024-03-28, Hasnain Faheem, Giraudo Bryan, and Christian Waage sold shares worth $26,773, $7,431, and $7,430, respectively, impacting their direct ownershi

    6/21/24 3:17:31 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care